Subsequently, it was thought that the combination of the newly designed dCK inhibitors with an RNR inhibitor could efficiently fight cancer cells and prevent escape mechanisms, as both pathways (the DNP and SP) would be simultaneously inhibited. This evidence concerns the gene NR2E3 and cancer.